Smith et al developed a prognostic index to evaluate patients with cutaneous B cell lymphoma. This can help identify patients who may benefit from more aggressive therapy. The authors are from Yale University.
Parameters:
(1) sites of involvement
(2) histology of the lymphoma
Sites of Involvement |
Significance |
---|---|
head and neck |
favorable |
arm |
favorable |
trunk |
unfavorable |
leg |
unfavorable |
disseminated |
unfavorable |
Histologic types:
(1) low grade
(2) diffuse large cell
(3) immunoblastic large cell
Histology |
Site |
Group |
---|---|---|
low grade |
any |
IA |
diffuse large cell |
favorable |
IB |
diffuse large cell |
unfavorable |
II |
immunoblastic |
favorable |
II |
immunblastic |
favorable |
III |
Group |
Odds Ratio Death |
5 Year Survival |
---|---|---|
IA |
1.0 |
94% |
IB |
1.3 |
86% |
II |
2.1 |
60% |
III |
4.5 |
34% |
Purpose: To evaluate a patient with cutaneous B-cell lymphoma using the prognostic index of Smith et al.
Specialty: Hematology Oncology, Dermatology
Objective: severity, prognosis, stage
ICD-10: C82, C83, C85,